CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CONNECTA Therapeutics is focused on developing new treatments for neurodevelopmental disorders linked to neuroplasticity dysfunction, particularly Fragile X Syndrome. Their investigational product, CTH120, aims to improve cognitive abilities and social inclusion for affected individuals through a network pharmacology a…
CONNECTA Therapeutics is a clinical biotech company developing new treatments for unmet Central Nervous System medical needs associated with neuroplasticity dysfunction, such as Fragile X Syndrome (FXS), a neurodevelopmental rare disease without a cure affecting around 1.8 M patients worldwide.
FXS is responsible for 30% of intellectual disability and cognitive deterioration in both males and females, starting at paediatric age and chronically persisting for life, impacting in learning abilities…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
